Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025362 (mental retardation)
 15,878 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

ABSTRACT Pemoline-induced self-biting behavior has been compared to similar self-injurious behavior (SIB) that occurs in the context of some mental retardation syndromes. The opiate antagonist, naltrexone, has been used successfully in the treatment of SIB in individuals with autism or mental retardation. This is the first report of the effect of naltrexone in an animal model of self-biting behavior. Naltrexone (0.01 mg/kg s.c.) significantly reduced the severity of self-biting behavior, but higher doses (0.10-10 mg/kg s.c.) had no such effect. Consistent with these results in the rat, a review of the clinical use of naltrexone in SIB is also suggestive of a relative loss of efficacy at higher doses (apparent therapeutic window). Naltrexone has higher affinity for mu receptors than other opioid receptor subtypes. Thus, the effect of naltrexone in treating SIB appears to be due to (mu-receptor interactions, with the loss of effect at higher doses due to supervening kappa receptor binding. Speculatively, one may ask if dosage reduction would convert naltrexone nonresponders to responders by lowering kappa receptor-mediated effects. Given the co-localization of opioids and dopamine inputs in some neurons, opioid-dopamine system interactions may also be important in pemoline-induced self-biting behavior.
 ...
PMID:Low-dose naltrexone inhibits pemoline-induced self-biting behavior in prepubertal rats. 1963 Jun 39